Travere Therapeutics (NASDAQ:TVTX) CFO Christopher Cline Sells 7,248 Shares

Key Points

• CFO Christopher Cline sold 7,248 shares on April 14 at an average price of $41.93 for about $303,909 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 117,913 shares (a 5.79% reduction, ~ $4.94M value).
• FDA granted full approval for Filspari in FSGS, expanding Travere’s rare-kidney franchise by an estimated ~30,000 U.S. patients and prompting a roughly 37% one-day share surge and multiple analyst price-target upgrades.
• Shares traded at $40.95 (down $1.18) with unusually high volume (~4.52M vs. a 2.20M average), a market cap of ~$3.78B and a one-year range of $13.88–$43.31, with elevated options activity suggesting higher short-term volatility.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher Cline sold 7,248 shares of the company's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.93, for a total transaction of $303,908.64. Following the completion of the transaction, the chief financial officer owned 117,913 shares in the company, valued at approximately $4,944,092.09. This trade represents a 5.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Performance

Travere Therapeutics stock traded down $1.18 during trading hours on Wednesday, hitting $40.95. The company had a trading volume of 4,521,912 shares, compared to its average volume of 2,203,580. The firm has a 50-day moving average of $29.57 and a 200 day moving average of $31.37. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70. The firm has a market cap of $3.78 billion, a PE ratio of -136.50 and a beta of 0.86. Travere Therapeutics, Inc. has a one year low of $13.88 and a one year high of $43.31.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming bought a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $37,000. Torren Management LLC bought a new position in Travere Therapeutics in the fourth quarter valued at approximately $38,000. Comerica Bank increased its stake in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock valued at $43,000 after acquiring an additional 492 shares during the last quarter. Smartleaf Asset Management LLC raised its position in Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock valued at $45,000 after purchasing an additional 487 shares in the last quarter. Finally, First Horizon Corp acquired a new position in Travere Therapeutics during the third quarter valued at approximately $36,000.

Analyst Ratings Changes

Several analysts recently weighed in on TVTX shares. Guggenheim lifted their price target on Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday. Wall Street Zen lowered Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. Canaccord Genuity Group increased their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday. Citigroup boosted their target price on shares of Travere Therapeutics from $48.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, HC Wainwright restated a "buy" rating and issued a $47.00 price target on shares of Travere Therapeutics in a research note on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $42.50.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.